Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

There are only limited treatment options for metastatic NRAS mutant melanoma patients with resistance to immune checkpoint inhibitors. Besides activation of the mitogen-activated protein (MAP) kinase pathway, they often have additional disturbances in cell cycle regulation. However, unlike BRAF muta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Forschner, Andrea, Sinnberg, Tobias, Mroz, Gabi, Schroeder, Christopher, Reinert, Christian Philipp, Gatidis, Sergios, Bitzer, Michael, Eigentler, Thomas, Garbe, Claus, Niessner, Heike, Röcken, Martin, Roggia, Cristiana, Armeanu-Ebinger, Sorin, Riess, Olaf, Mattern, Sven, Nann, Dominik, Bonzheim, Irina
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7959243/
https://ncbi.nlm.nih.gov/pubmed/33732653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.643156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados